Patrys Limited

PAB.ASX

Health Care

Development of natural human antibody-based therapies for the treatment of life threatening diseases including cancer.

Market Data

Price

$0.043

-0.0%
Market Cap

$30.0M

P/E Ratio

-100000.0x

EPS

$-0.019

Div. Yield

0.00%

52-Week Change

+0.3%

Latest Earnings

Appendix 4D - Half Year Accounts - 31 December 2025

26 February 2026

NPAT
-$3.02
-98.7% YoY
EPS
$-0.01

Patrys Limited reported a significantly increased loss of $3.02M for H1 FY26, up 98.7% from $1.52M in the prior period, primarily driven by $1.77M in share-based payment expenses. The company completed a strategic transformation by acquiring Reliis Pty Ltd (adding CNS therapeutic RLS-2201) and raised $1.77M in capital, ending with cash of $1.90M versus $742k at June 2025. Key points: Successfully completed acquisition of Reliis Pty Ltd adding clinical-stage CNS asset RLS-2201; Raised $1.77M in capital strengthening cash position to $1.90M from $742k at June 2025; Established dual-platform strategy diversifying risk with nearer-term regulatory catalysts

Recent Announcements

26 Feb 2026 Actual Results Neutral

Appendix 4D - Half Year Accounts - 31 December 2025

Patrys Limited reported a significantly increased loss of $3.02M for H1 FY26, up 98.7% from $1.52M in the prior period, primarily driven by $1.77M in share-based payment expenses. The company completed a strategic transformation by acquiring Reliis Pty Ltd (adding CNS therapeutic RLS-2201) and raised $1.77M in capital, ending with cash of $1.90M versus $742k at June 2025. Key points: Successfully completed acquisition of Reliis Pty Ltd adding clinical-stage CNS asset RLS-2201; Raised $1.77M in capital strengthening cash position to $1.90M from $742k at June 2025; Established dual-platform strategy diversifying risk with nearer-term regulatory catalysts

Get real-time alerts for PAB

Receive AI-powered earnings summaries and instant notifications when Patrys Limited releases results.

Register Free